Daclatasvir Dihydrochloride and Fedratinib Hydrochloride

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme. When a single 10 mg dose of daclatasvir was administered following pretreatment with the potent CYP450 3A4 inhibitor ketoconazole (400 mg once daily), daclatasvir peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.6- and 3-fold, respectively. No data are available for other, less potent CYP450 3A4 inhibitors. MANAGEMENT: Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb, Princeton, NJ. Cerner Multum, Inc. "Australian Product Information." O 0

MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme. When a single 10 mg dose of daclatasvir was administered following pretreatment with the potent CYP450 3A4 inhibitor ketoconazole (400 mg once daily), daclatasvir peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.6- and 3-fold, respectively. No data are available for other, less potent CYP450 3A4 inhibitors.

MANAGEMENT: Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.

Daclatasvir Dihydrochloride

Generic Name: daclatasvir

Brand name: Daklinza

Synonyms: Daclatasvir

What is Daclatasvir Dihydrochloride?

Fedratinib Hydrochloride

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: Fedratinib

What is Fedratinib Hydrochloride?